SBIR/STTR Research Award

qBead Assessment of miRNA in Alzheimer's Disease

Award identifier ff8264380540d6dcaf621fbccf93b28461d890de3ceb46f70521d09929ac3be0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$309,019

Program and phase

SBIR · Phase I

Award year

2011

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
HIGH THROUGHPUT GENOMICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
JRN1EHHSYAB4
Solicitation number
PA10-050
Topic code
NIA

Research abstract

DESCRIPTION (provided by applicant): miRNA biomarkers related to Alzheimer's disease (AD) that may be useful as a diagnostic tool or in elucidating the mechanisms of disease and discovery of novel therapeutics will be identified using a novel whole transcriptome qBead X-MAP-based assay (not yet launched commercially). Biomarkers will be identified from brain formalin fixed (FFPE) tissue and matched serum samples of AD patients, patients diagnosed Parkinson's disease and dementia (PD), patients with cerebrovascular disease neuropathologically diagnosed as vascular dementia (VaD), and normal controls (NC). The results will be validated using matched frozen tissue and both the qBead assay and PCR. The qBead X-MAP assay utilizes the quantitative Nuclease Protection Assay (qNPA ) and measures both miRNA and mRNA. It is very precise and sensitive. This program will exploit the qBead assay to validate the utility of FFPE and serum for identification of AD biomarkers, to confirm recent reports of altered miRNA levels in frozen brain of AD patients, and to provide an early example of an application of the qBead whole transcriptome miRNA assay. In Phase II mRNA biomarkers will be included and the studies expanded to a larger training set of AD, PD, VaD and NC FFPE, serum, buffy coat, and plasma samples to expand the biomarker set and then test an independent set of samples to confirm/validate the biomarkers. PUBLIC HEALTH RELEVANCE: miRNA biomarkers of Alzheimer's disease (AD) useful for diagnosis, for identifying mechanisms of disease, and as targets for drug discovery will be identified from brain FFPE and serum using a novel whole transcriptome qBead X-MAP-based assay that has not yet been launched commercially. The qBead X-MAP assay utilizes the quantitativeNuclease Protection Assay (qNPA ) and measures both miRNA and mRNA. It is very precise and sensitive and will enable the identification of low abundant miRNA and those that change by as little as 1.2-fold. Such small changes can be particularly relevant intissues where a 1.2-fold change in a target population of cells making up only 40% of the sample may reflect a 50% change in those cells.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

13 SBIR/STTR records share this UEI (2000–2013). Reported award amounts total $5,895,147. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.